Pharmaceuticals

Gene Therapy On Neurological Diseases Market Research: Growth Projections and Trends 2030

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gene therapy on neurological diseases market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Gene Therapy On Neurological Diseases Market in 2026, and what figure is it projected to hit by 2030?

The gene therapy on neurological diseases market size has experienced swift expansion in recent years. Projections show its value will climb from $3.55 billion in 2025 to $4.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.0%. The market’s historical development can be ascribed to factors including limited gene therapy options for neurological diseases, the increasing prevalence of Alzheimer’s and Parkinson’s disease, an ongoing reliance on conventional treatment methods, a heightened awareness of genetic approaches, and the early clinical trials of viral vectors.

The gene therapy on neurological diseases market size is anticipated to experience substantial growth in the upcoming years, projected to reach $6.48 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 12.7%. This growth over the forecast period is driven by factors such as the development of adeno-associated virus and lentiviral therapies, the expansion of non-viral delivery platforms, an increase in regulatory approvals for neurological gene therapies, heightened investment in research and development for targeted genetic interventions, and the integration of digital monitoring and AI-based patient management. Prominent trends for the forecast period include a rise in investment across viral and non-viral gene therapy platforms, the broadening of gene therapy applications for various neurological disorders, an intensified focus on personalized and targeted genetic treatments, an expansion in hospital and clinic-based gene therapy programs, and the creation of advanced delivery methods for neurological gene therapy.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

Which Drivers Are Affecting Market Participation In The Gene Therapy On Neurological Diseases Market?

The rising occurrence of neurological conditions is projected to boost the expansion of the gene therapy on neurological diseases market moving ahead. These disorders are health issues impacting the brain, spinal cord, and nerves, resulting in various symptoms like cognitive, motor, and sensory deficits. The growing incidence of neurological disorders is associated with an older demographic, given that aging progressively hinders neuronal activity, decreases brain adaptability, and heightens oxidative stress, thereby fostering the onset and advancement of such conditions. Gene therapy on neurological diseases assists in managing these disorders by addressing their underlying genetic origins, providing possible enduring or lasting treatment options. This therapy enhances patient results by restoring or altering gene function, alleviating symptoms, and lessening the need for repeated medical procedures, thus improving the overall quality of life. An example is provided by the National Health Service, a UK-based government agency, stating that in July 2024, 487,432 patients had been diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, marking an increase of 3,155 cases from May 31, 2024. Consequently, the rising occurrence of neurological conditions is fueling the expansion of the gene therapy on neurological diseases market.

What Segment Classifications Make Up The Gene Therapy On Neurological Diseases Market?

The gene therapy on neurological diseases market covered in this report is segmented –

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

What Industry Trends Are Transforming The Gene Therapy On Neurological Diseases Market?

Major companies operating in the gene therapy for neurological diseases market are prioritizing the development of advanced viral delivery systems, such as the adeno-associated virus serotype 2 (AAV2) vector, to enhance targeted gene delivery, improve efficacy, mitigate immune reactions, and enable long-lasting treatments. The Adeno-associated virus serotype 2 (AAV2) vector functions as a modified, non-pathogenic viral delivery system in gene therapy, designed to transport therapeutic genes into specific target cells, particularly neurons, for prolonged expression. For instance, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for a gene therapy intended for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy employs an AAV2 vector to deliver a functional DDC gene copy into the putamen, facilitating dopamine production and improving motor functions. It involves a single, intraputaminal infusion structured to deliver sustained therapeutic benefits, significantly enhancing motor function and reducing debilitating symptoms without the need for repeated interventions.

Which Leading Companies Dominate The Gene Therapy On Neurological Diseases Market Share?

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

How Does The Gene Therapy On Neurological Diseases Market Perform Across Major Global Regions?

North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gene Therapy On Neurological Diseases Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp

Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2026, By The Business Research Company

Switchboard Market Report 2026

https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report

Mobile Computer Market 2026

https://www.thebusinessresearchcompany.com/report/mobile-computer-market

Surfing Boards Market Report 2026

https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795